HERCULES, CA–Jun 1, 2009 — Bio-Rad Laboratories, Inc. (NYSE:BIO – News) and (NYSE:BIO-B – News), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the FDA clearance of two new multiplex infectious disease serology panels for use on the BioPlex® 2200 system: the BioPlex ToRC IgG panel and the BioPlex HSV-1 & HSV-2 IgG panel. The BioPlex 2200 system is a fully automated, random access platform that employs multiplexing technology to analyze multiple disease markers from a single patient sample.

The ToRC IgG kit simultaneously detects IgG class antibodies to Toxoplasma gondii (T. gondii), Rubella, and Cytomegalovirus (CMV). T. gondii, Rubella, and CMV can cause a variety of serious conditions in an unborn fetus including blindness, retardation, and death. The HSV-1 & HSV-2 IgG kit utilizes type-specific proteins to simultaneously detect and differentiate IgG class antibodies to the two most common herpes subtypes, HSV-1 and HSV-2. The ToRC IgG kit is available for sale and the HSV kit is pending launch.

“The launch of the ToRC IgG kit and upcoming launch of the HSV-1 & HSV-2 IgG kit are two significant steps in expanding the BioPlex 2200 serology testing menu,” said John Goetz, Bio-Rad Vice President and Group Manager Clinical Diagnostics. “Using these two products, laboratories will be able to take advantage of the power and efficiency of multiplexing. Later this year we look forward to launching additional panels, further expanding our infectious disease serology and autoimmune menu for the platform.”

The BioPlex 2200 system is the first and only fully-automated, random access multiplex testing system and provides clinical laboratories with the capability to rapidly process or “multiplex” multiple individual tests that are traditionally processed separately using a single small volume patient sample.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE:BIO – News) and (NYSE:BIO-B – News), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.